This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Company News for Sep 7, 2023
by Zacks Equity Research
Companies In The News Are: AVAv, ASND, HQY, PLAB.
Wall Street Analysts Predict a 41.43% Upside in Ascendis Pharma A/S (ASND): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 41.4% in Ascendis Pharma A/S (ASND). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
How Much Upside is Left in Ascendis Pharma A/S (ASND)? Wall Street Analysts Think 47.35%
by Zacks Equity Research
The mean of analysts' price targets for Ascendis Pharma A/S (ASND) points to a 47.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Pfizer (PFE) Gets FDA Nod for Growth Hormone Deficiency Drug
by Zacks Equity Research
The FDA approves Pfizer (PFE) and OPKO Health's (OPK) Ngenla to treat growth hormone deficiency in pediatric patients. The drug's commercial launch is expected this August.
Ascendis Pharma A/S (ASND) Soars 8.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Ascendis Pharma A/S (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
The Zacks Analyst Blog Highlights bluebird, Oncternal Therapeutics, Avidity, Ascendis and Vertex Pharmaceuticals
by Zacks Equity Research
bluebird, Oncternal Therapeutics, Avidity, Ascendis and Vertex Pharmaceuticals are included in this Analyst Blog.
Biotech Stock Roundup: BLUE Announces Q4 Results, ONCT, ASND & RNA Fall on Updates
by Zacks Equity Research
Earnings and pipeline updates from bluebird bio (BLUE) and Avidity (RNA) are the key highlights for the biotech sector.
Ascendis (ASND) Down on Hypoparathyroidism Drug NDA Deficiencies
by Zacks Equity Research
The FDA identifies deficiencies in Ascendis' (ASND) regulatory filing for TransCon PTH in hypoparathyroidism. This might lead to an extended review timeline of the company's filing.
Omega Therapeutics, Inc. (OMGA) Moves 15.2% Higher: Will This Strength Last?
by Zacks Equity Research
Omega Therapeutics, Inc. (OMGA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Does Ascendis Pharma AS (ASND) Have the Potential to Rally 35% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 34.6% upside potential for Ascendis Pharma AS (ASND). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Can Elevance Health (ELV) Beat Q2 Earnings on Membership Growth?
by Zacks Equity Research
Elevance Health's (ELV) second-quarter results are likely to reflect improved Commercial Business operations, driven by the robust growth in risk-based areas.
Why Ascendis Pharma (ASND) Might Surprise This Earnings Season
by Zacks Equity Research
Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why Encompass Health (EHC) is Down 2.4% Since Q1 Earnings Beat
by Zacks Equity Research
Encompass Health Corporation (EHC) looks to unveil eight additional de novo locations this year and increase its bed count.
Vermilion Energy (VET) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
A favorable commodity pricing scenario is likely to have aided Vermilion Energy's (VET) earnings in Q1.
Teladoc (TDOC) Plunges 40.3% Since Q1 Earnings Beat: Here's Why
by Zacks Equity Research
Teladoc Health's (TDOC) bet on mental health service BetterHelp is likely to generate lower yield this year.
Ring Energy (REI) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
A favorable commodity pricing scenario is likely to have aided Ring Energy's (REI) earnings in Q1.
Should You Buy Ascendis Pharma (ASND) Ahead of Earnings?
by Aditi Saraogi
Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Ascendis Pharma AS (ASND) Surges 6.5%: Is This an Indication of Further Gains?
by Zacks Equity Research
Ascendis Pharma AS (ASND) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Pfizer's (PFE), OPKO's BLA for Somatrogon Gets CRL From FDA
by Zacks Equity Research
The FDA issues a Complete Response Letter to Pfizer (PFE) and OPKO Health's biologics license application for somatrogon to treat growth hormone deficiency in pediatric patients.
Ascendis' (ASND) TransCon hGH Gets EU Nod for Pediatric GHD
by Zacks Equity Research
Ascendis Pharma (ASND) gets nod in Europe for TransCon hGH for the treatment of pediatric growth hormone deficiency.
Ascendis (ASND) Gets Positive CHMP Opinion for GHD Drug Filing
by Zacks Equity Research
Ascendis Pharma (ASND) is seeking approval for TransCon hGH for the treatment of pediatric growth hormone deficiency in Europe.
AstraZeneca (AZN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
AstraZeneca's(AZN) third-quarter results are expected to reflect the impact of strong demand for new drugs. Investors are likely to focus on sales numbers of AstraZeneca's COVID-19 vaccine.
Is a Beat in Store for BioNTech (BNTX) This Earnings Season?
by Zacks Equity Research
On BioNTech's (BNTX) third-quarter earnings call, investors' focus is expected to be on the sales performance of Comirnaty, its COVID-19 vaccine developed in partnership with Pfizer.
Organon (OGN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Organon (OGN) is set to provide updates on its earnings and revenues when it reports third-quarter 2021 results.
Ascendis (ASND) Seeks FDA Nod for New Immunotherapy Study
by Zacks Equity Research
Ascendis (ASND) plans to develop a sustained-release immunotherapy to treat advanced cancer developed using its TransCon platform.